

**June 26, 2019, Multijurisdictional Contractor Advisory Committee (CAC) Meeting  
Bibliography**

1. Mancinelli L, Cronin M, Sadée WJAP. Pharmacogenomics: the promise of personalized medicine. 2000;2(1):29-41.
2. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2017 National Survey on Drug Use and Health (HHS Publication No. SMA 18-5068, NSDUH Series H-53). 2018; <https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHFFR2017/NSDUHFFR2017.htm#mde2>. Accessed 1/31/2019.
3. Valiengo LdCL, Stella F, Forlenza OV. Mood disorders in the elderly: prevalence, functional impact, and management challenges. *Neuropsychiatric disease and treatment*. 2016;12:2105-2114.
4. Gartlehner G, Gaynes BN, Amick HR, et al. Nonpharmacological Versus Pharmacological Treatments for Adult Patients With Major Depressive Disorder. Agency for Healthcare Research and Quality;2015.
5. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\*D: implications for clinical practice. *Am J Psychiatry*. 2006;163(1):28-40.
6. MacQueen G, Santaguida P, Keshavarz H, et al. Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults. *Can J Psychiatry*. 2017;62(1):11-23.
7. Altar CA, Hornberger J, Shewade A, Cruz V, Garrison J, Mrazek D. Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. *Int Rev Psychiatry*. 2013;25(5):509-533.
8. Singh AB. Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report. *Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology*. 2015;13(2):150-156.
9. Brennan FX, Gardner KR, Lombard J, et al. A naturalistic study of the effectiveness of pharmacogenetic testing to guide treatment in psychiatric patients with mood and anxiety disorders. 2015;17(2).
10. Pérez V, Salavert A, Espadaler J, et al. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. *BMC psychiatry*. 2017;17(1):250-250.
11. Han C, Wang S-M, Bahk W-M, et al. A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. *Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology*. 2018;16(4):469-480.
12. Hall-Flavin DK, Winner J, Allen J, et al. Using a pharmacogenomic algorithm to guide the treatment of depression. 2012;2(10):e172.
13. Hall-Flavin DK, Winner JG, Allen JD, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. 2013;23(10):535-548.
14. Winner J, Allen JD, Altar CA, Spahic-Mihajlovic A. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. *Transl Psychiatry*. 2013;3:e242.

15. Winner JG, Carhart JM, Altar A, Allen JD, Dechairo BMJDm. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. 2013;16(89):219-227.
16. Macaluso M, Preskorn SHJJoPP. Knowledge of the pharmacology of antidepressants and antipsychotics yields results comparable with pharmacogenetic testing. 2018;24(6):416-419.